ISAL 2019 | Bispecific antibodies for R/R AML: ongoing clinical trials
Bispecific antibodies are moving from strength to strength, with a multitude in clinical trials. Here, John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses the bispecific antibodies under investigation for relapsed/refractory acute myeloid leukemia (AML), typically targeting CD123, CD33 or CLL1. Prof. DiPersio was speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up